Overweight Clinical Trials in Knoxville, Tennessee

4 studies are recruiting for overweight in Knoxville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

    Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    New Phase Research & Development /ID# 282131, Knoxville, Tennessee
    Locations
    45 in total
    Run by
    AbbVie

    See if you can join NCT07752979 on ClinicalTrials.gov

  2. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    Stage
    Phase 3
    Ages
    45 to 99
    Site
    Accellacare of Knoxville, Knoxville, Tennessee
    Locations
    783 in total
    Run by
    Amgen

    See if you can join NCT07037433 on ClinicalTrials.gov

  3. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    New Phase Research and Development, Knoxville, Tennessee
    Locations
    87 in total
    Run by
    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

  4. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-1 Research Site, Knoxville, Tennessee
    Locations
    71 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.